Aclaris Therapeutics (NASDAQ:ACRS) Issues Earnings Results, Misses Expectations By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01), Zacks reports. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

Aclaris Therapeutics Stock Down 7.2 %

NASDAQ:ACRS traded down $0.15 during mid-day trading on Thursday, hitting $1.95. 638,470 shares of the company traded hands, compared to its average volume of 769,210. The stock’s fifty day moving average price is $2.47 and its 200-day moving average price is $2.15. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17. The firm has a market cap of $139.15 million, a price-to-earnings ratio of -3.75 and a beta of 0.50.

Analyst Upgrades and Downgrades

ACRS has been the topic of several recent research reports. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald upgraded Aclaris Therapeutics to a “strong-buy” rating in a research report on Thursday, January 30th. BTIG Research upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Tuesday, November 19th. Finally, Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Aclaris Therapeutics has a consensus rating of “Buy” and an average target price of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.